肺动脉是否应作为不可手术非小细胞肺癌根治性放疗的剂量限制器官
本研究在另一独立中心回顾性分析141例接受根治性常规分割放疗或放化疗的不可手术非小细胞肺癌患者,评估肺动脉和心脏剂量学参数对生存的影响。结果显示肺动脉受侵分级和PA V40-55与总生存显著相关,而心脏剂量学参数无显著关联,提出肺动脉应被视为剂量限制器官。
要点
- 肺动脉受侵分级越高,中位总生存越短(0-3级分别为41.8、27.8、12.7、7.5个月,P<0.001)。
- PA V40、V45、V50、V55阈值分别为80%、68%、45%、32%时为总生存独立预测因子。
- 心脏剂量学参数与总生存无显著关联,支持肺动脉作为剂量限制器官。
核心结论
- 肺动脉受侵分级和PA V40-55与接受根治性常规分割放疗的非小细胞肺癌患者总生存相关,建议将肺动脉视为剂量限制器官。
研究设计与样本
- 回顾性分析2010年8月至2014年9月连续141例医学上不可手术或不可切除的非小细胞肺癌患者,接受根治性放疗或放化疗。
主要发现
- 中位随访16.9个月,中位总生存20.5个月(95%CI 10.3-30.7个月),1、2、3年总生存率分别为75.2%、58.2%、56%。
- 单因素和多因素分析显示KPS评分、CCI、T和N分期、肺动脉受侵分级及PA V40-55与总生存显著相关。
- 心脏剂量学因素与总生存无显著关联。
- 肺动脉受侵分级0、1、2、3级的中位总生存分别为41.8、27.8、12.7、7.5个月(P<0.001)。
- PA V40、V45、V50、V55分别以80%、68%、45%、32%为阈值时是总生存的独立预测因子。
临床怎么用
- 在制定非小细胞肺癌根治性放疗计划时,应评估肺动脉受侵分级并限制PA V40-55,以可能改善总生存。
局限性
- 本研究为单中心回顾性分析,样本量141例,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our previous study suggested that some pulmonary artery (PA) dosimetric parameters were associated with mortality in unresectable non-small cell lung cancer (NSCLC) treated with definitive radiotherapy. The present study aims to analyze the impact of both PA and heart dosimetric parameters on survival of patients with NSCLC treated with definitive conventional fractionated radiotherapy (CFRT) in another independent research center and further determine whether the PA should be considered a dose-limiting organ at risk (OAR) for patients receiving thoracic CFRT. METHODS: We performed a retrospective analysis of successive patients with medically inoperable or unresectable NSCLC treated with definitive radiotherapy or chemoradiotherapy from August 2010 to September 2014. Clinical and pathological information, PA and heart dosimetric factors, and follow-up data were collected from each patient's records and evaluated as potential prognostic factors for survival. Survival probabilities were estimated by the Kaplan-Meier method and compared by the log rank test. Cox proportional hazards regression models were performed to determine the independent predicators of survival. The optimal cutoff points of continuous dosimetric variables were determined by Youden index in receiver operating characteristic (ROC) analysis. RESULTS: This study analyzed the records of 141 patients, 50.4% had adenocarcinoma, 71.6% had stage III disease, and 55% patients received concurrent chemoradiotherapy. Radiation dose ranged from 60 to 76 Gy in 30-38 fractions. Median follow up was 16.9 months. Median overall survival (OS) was 20.5 months (95% confidence interval [CI] 10.3-30.7 months), and 1-, 2-, 3-year OS rates were 75.2%, 58.2% and 56%, respectively. Univariate and multivariate analysis showed that Karnofsky Performance Status (KPS) score, Charlson's Comorbidity Index (CCI), T and N stage, PA invasion grade and the percentage of PA volume that received 40 to 55 Gy (PA V40-55) were significantly associated with OS. No significant associations were found between heart dosimetric factors and OS. Median OS of patients with PA invasion grade 0, 1, 2, and 3 were 41.8, 27.8, 12.7 and 7.5 months, respectively (P < 0.001). PA V40, V45, V50 and V55, using thresholds of 80%, 68%, 45%, and 32%, respectively, were independent predictors for OS. CONCLUSIONS: PA invasion grade and PA V40-55 appear associated with OS in patients with NSCLC treated with definitive CFRT. We propose that PA be considered as a dose-limiting OAR for such patients.
引用
- Ma JT, Sun L, Sun X, et al. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy? Radiat Oncol. 2017. PMID: 28143532. doi:10.1186/s13014-017-0772-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。